Do All Critically Ill Patients with COVID-19 Disease Benefit from Adding Tocilizumab to Glucocorticoids? A Retrospective Cohort Study

Background: Treatment guidelines recommend the tocilizumab use in patients with a CRP of >7.5 mg/dL. We aimed to estimate the causal effect of glucocorticoids + tocilizumab on mortality overall and after stratification for PaO(2)/FiO(2) ratio and CRP levels. Methods: This was an observational coh...

Descripción completa

Detalles Bibliográficos
Autores principales: Mussini, Cristina, Cozzi-Lepri, Alessandro, Meschiari, Marianna, Franceschini, Erica, Burastero, Giulia, Faltoni, Matteo, Franceschi, Giacomo, Iadisernia, Vittorio, Volpi, Sara, Dessilani, Andrea, Gozzi, Licia, Conti, Jacopo, Del Monte, Martina, Milic, Jovana, Borghi, Vanni, Tonelli, Roberto, Brugioni, Lucio, Romagnoli, Elisa, Pietrangelo, Antonello, Corradini, Elena, Girardis, Massimo, Busani, Stefano, Cossarizza, Andrea, Clini, Enrico, Guaraldi, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967307/
https://www.ncbi.nlm.nih.gov/pubmed/36851508
http://dx.doi.org/10.3390/v15020294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967307/
https://www.ncbi.nlm.nih.gov/pubmed/36851508
http://dx.doi.org/10.3390/v15020294

Ejemplares similares